Skip to main content
Mark Moasser, MD, Oncology, San Francisco, CA

Mark M Moasser MD

Oncology•San Francisco, CA

Professor, Medicine, UCSF School of Medicine

Join to view full profile

  • 1825 fourth streetSan Francisco, CA 94158

  • Phone+1 415-353-7070

  • Fax+1 415-353-7021

Dr. Moasser is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Moasser's full profileAlready have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1996
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1988 - 1991
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1988

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - 2027
  • NY State Medical License
    NY State Medical License 1989 - 2005
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2017

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models
    Mark Moasser, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Trial Confirms That Perjeta Extends Survival in Metastatic Breast Cancer
    Trial Confirms That Perjeta Extends Survival in Metastatic Breast CancerSeptember 28th, 2014

Grant Support

  • Understanding Resistance To HER Family Tyrosine Kinase InhibitorsNational Cancer Institute2007–2011
  • Adhesion Signaling By A Novel Mitotic Substrate Of SRCNational Cancer Institute2005–2009
  • Pilot Studies To Develop Probes For In Vivo Imaging Of P13k/Akt Pathway ActivityNational Cancer Institute2007–2008

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Mark Moasser, Dr. Mark Moasser, MD, Dr. M Moasser, Dr. Mark M Moasser